Adding a new antibody treatment to maintenance therapy for blood cancer

This trial is testing whether linvoseltamab—a new antibody-based medication—works better when added to lenalidomide (a standard maintenance drug) for patients with multiple myeloma. The study wants to see if this combination can get rid of any remaining cancer cells that may be hiding in your body, or help patients whose cancer has started to come back regain remission.

After initial treatment for multiple myeloma, some patients still have a small number of cancer cells remaining even though their disease looks controlled. For others, the cancer returns despite maintenance therapy. This medication is being tested to see if it can target and eliminate those leftover cells or help patients recover remission when their disease relapses.